Next Article in Journal
Assessing Vaccine Hesitancy among Healthcare Workers: A Cross-Sectional Study at an Italian Paediatric Hospital and the Development of a Healthcare Worker’s Vaccination Compliance Index
Previous Article in Journal
Measles Virus Infection and Immunity in a Suboptimal Vaccination Coverage Setting
Open AccessArticle

Selective Persistence of HPV Cross-Neutralising Antibodies following Reduced-Dose HPV Vaccine Schedules

1
Infection and Immunity, Murdoch Children’s Research Institute, Parkville, VIC 3052, Australia
2
Department of Paediatrics, The University of Melbourne, Parkville, VIC 3052, Australia
3
Ministry of Health and Medical Services, Suva 679, Fiji
4
Diamantina Institute, The University of Queensland, Brisbane, QLS 4072, Australia
5
Department of Obstetrics and Gynecology, University of Melbourne, Parkville, VIC 3052, Australia
6
Regional WHO HPV Reference Laboratory, Centre Women’s Infectious Diseases Research, The Royal Women’s Hospital, Parkville, VIC 3052, Australia
7
Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK
8
Department of Child Health, Menzies School of Health Research, Darwin, NT 0811, Australia
*
Author to whom correspondence should be addressed.
Both authors contributed equally.
Vaccines 2019, 7(4), 200; https://doi.org/10.3390/vaccines7040200
Received: 6 November 2019 / Revised: 20 November 2019 / Accepted: 26 November 2019 / Published: 28 November 2019
The duration of cross-neutralising antibody responses (cross-NAb) following HPV immunisation is unknown. We compared cross-NAb responses in cohort of girls who were either unimmunised or had received immunisation with one, two or three doses of 4vHPV (Gardasil®, Merck Inc., Kenilworth, NJ, USA) six years earlier, before and one month after a booster dose of 2vHPV (Cervarix®, GSK, Brentford, UK). NAb to potentially cross-reactive HPV genotypes 31, 33, 45, 52 and 58 were measured using a HPV pseudovirion-based neutralisation assay. Girls who had previously received at least one dose of 4vHPV had significantly higher NAb titres for HPV31 when compared with unimmunised girls, whereas no difference in NAb titre was observed for four other genotypes (33, 45, 52 and 58). Following a single further immunisation with 2vHPV, NAb titres to each of the five tested HPV genotypes were comparable for girls who previously received one, two or three doses of 4vHPV, and were significantly higher than for previously unimmunised girls. Immunisation with one, two or three doses of 4vHPV induced NAb to HPV31 that persisted for six years, but there was no persistence of NAb to HPV33, 45, 52 or 58. Our results suggest that one or two doses of 4vHPV may provide long-term protection against HPV31. View Full-Text
Keywords: human papillomavirus vaccine; reduced doses; cross-neutralising antibodies; low- and middle-income countries human papillomavirus vaccine; reduced doses; cross-neutralising antibodies; low- and middle-income countries
Show Figures

Figure 1

MDPI and ACS Style

Toh, Z.Q.; Kosasih, J.; Russell, F.M.; Reyburn, R.; Fong, J.; Tuivaga, E.; Ratu, F.T.; Nguyen, C.D.; Matanitobua, S.; Do, L.A.H.; Menheniott, T.; Frazer, I.H.; Garland, S.M.; Mulholland, E.K.; Licciardi, P.V. Selective Persistence of HPV Cross-Neutralising Antibodies following Reduced-Dose HPV Vaccine Schedules. Vaccines 2019, 7, 200.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop